Agile Therapeutics, Inc. (AGRX)
Company Description
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States.
Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
| Country | United States |
| Founded | 1997 |
| IPO Date | May 23, 2014 |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Employees | 30 |
| CEO | Alfred Altomari |
Contact Details
Address: 101 Poor Farm Rd Princeton, New Jersey 08540-1941 United States | |
| Phone | 609 683 1880 |
| Website | agiletherapeutics.com |
Stock Details
| Ticker Symbol | AGRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 0001261249 |
Key Executives
| Name | Position |
|---|---|
| Alfred F. Altomari | Chairman and Chief Executive Officer |
| Geoffrey P. Gilmore | Senior Vice President, General Counsel and Corporate Secretary |
| Dr. Paul Korner M.B.A., M.D. | Senior Vice President and Chief Medical Officer |
| Dennis P. Reilly | Senior Vice President and Chief Financial Officer |
| Jason Butch | Vice President and Chief Accounting Officer |
| Matthew Riley | Head of Investor Relations and Corporate Communications |
| Amy Welsh | Vice President of Marketing |
| Robert G. Conway M.E. | Senior Vice President and Chief Supply Chain Officer |
| Dr. Elizabeth Ijeoma Onyemelukwe Garner M.D., M.P.H. | Consultant |
| Joseph D'Urso | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 24, 2022 | 8-K | Current report |
| May 23, 2022 | 8-K | Current report |
| May 13, 2022 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| May 12, 2022 | 10-Q | Quarterly report [Sections 13 or 15(d)] |
| May 12, 2022 | 8-K | Current report |
| Apr 29, 2022 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2022 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2022 | 8-K | Current report |
| Apr 27, 2022 | 424B5 | Prospectus [Rule 424(b)(5)] |
| Apr 26, 2022 | 8-K | Current report |
| View All SEC Filings | ||